Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the effect of HuMax-CD4, as a treatment for
advanced stage (late stage) cutaneous T-cell lymphoma (CTCL). Almost all patients who are
affected by late stage CTCL have many cancerous cells which bear a receptor called CD4.
HuMax-CD4 is an investigational drug directed against this receptor. There is no placebo in
this trial; all patients will be treated with HuMax-CD4. The response rates, duration of
responses, relief of symptoms, and safety profile of HuMax-CD4 will be evaluated during this
trial.